Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant

J Gen Virol. 2004 Jan;85(Pt 1):131-135. doi: 10.1099/vir.0.19592-0.

Abstract

A murine gammaherpesvirus-68 (MHV-68) mutant with deregulated transcription of its ORF50 transactivator was severely impaired in latency establishment. The deregulated virus showed reduced immunogenicity, probably reflecting a lower antigen load. However, it still elicited effective immunity to a subsequent wild-type (WT) virus challenge. Infection was not completely prevented, but was very substantially reduced in extent and the long-term level of WT viral DNA in lungs and spleens remained low. Thus latency-deficient MHV-68 illustrates a possible general approach to creating attenuated gammaherpesvirus vaccines that can protect against pathogenic WT infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Antibodies, Viral / blood
  • DNA, Viral / analysis
  • DNA, Viral / isolation & purification
  • Gammaherpesvirinae / genetics
  • Gammaherpesvirinae / immunology*
  • Gammaherpesvirinae / pathogenicity
  • Gene Expression Regulation, Viral
  • Herpesviridae Infections / immunology*
  • Herpesviridae Infections / prevention & control*
  • Immunity, Cellular
  • Lung / virology
  • Mice
  • Mice, Inbred C57BL
  • Mutation*
  • Spleen / virology
  • Vaccination
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology*
  • Virus Latency / genetics*
  • Virus Latency / physiology

Substances

  • Antibodies, Viral
  • DNA, Viral
  • Viral Vaccines